Adding belzutifan to pembrolizumab after kidney cancer surgery cuts recurrence risk by 28%, helping high-risk patients stay ...

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

The LITESPARK-022 study tested belzutifan, an oral small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α) targeting angiogenesis, in combination with standard of care pembrolizumab as ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

While drugs like Keytruda are often described as breakthroughs, the study shows that their price places them far beyond the reach of the majority of patients who may need them.

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...